8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Bristol Myers Squibb’s closed up 1.6% at $65.46 on Friday, after the US pharma major bagged another indication for its blockbuster immuno-oncology drug Opdivo (nivolumab), and this came well ahead of the prescription drug user fee act (PDUFA) goal date for a decision on the immunotherapy regimen of May 25. 17 April 2021
The US Food and Drug Administration on Friday revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. 17 April 2021
US health technology assessor the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of UK drugmaker GlaxoSmithKline’s Benlysta (belimumab) and Canadian firm Aurinia’s Lupkynis (voclosporin) for the treatment of lupus nephritis (LN). 16 April 2021
Roche today announced new Ocrevus (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing. 16 April 2021
A licensing deal between XOMA Corporation and Affimed Therapeutics is starting to bear fruit, with progress in three innate cell engager (ICE) programs. 16 April 2021
The European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody. 16 April 2021
The approval of a Food and Drug Administration (FDA) emergency use authorization (EUA) for AstraZeneca’s COVID-19 vaccine AZD1222, now dubbed Vaxzevria, will boost confidence and use of the vaccine globally. 16 April 2021
For biotech companies, the prospect of receiving non-dilutive, non-recourse funding to advance their assets even through the early stages of clinical development may sound too good to be true. 16 April 2021
California, USA-based biotech BioAge Labs has entered into an exclusive worldwide license agreement with Amgen to develop and commercialize Amgen’s clinical-stage APJ agonist, BGE-105 previously (named AMG 986 by Amgen) to ameliorate muscle aging. 15 April 2021
Cambridge, UK-based biotech Alchemab Therapeutics today announced the completion of a £60 million ($82 million) Series A financing round. 15 April 2021
The National Institute for Care and Health Excellence’s (NICE) has recommended Ultomiris (ravulizumab) for use in the National Health Service (NHS) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). 15 April 2021
UK endocrine diseases specialist Diurnal Group has withdrawn its application for maintenance of orphan designation in Europe for Efmody (hydrocortisone modified-release hard capsules), a drug formerly known as Chronocort. 15 April 2021
US pharma giant Merck & Co today announced it will discontinue the development of MK-7110 (formerly known as CD24Fc) for the treatment of hospitalized patients with COVID-19. 15 April 2021
PTC Therapeutics has announced new data showing continued improvements in motor milestones in infants with type 1 spinal muscular atrophy (SMA) after two years of treatment with Evrysdi (risdiplam). 15 April 2021
UK pharma major GlaxoSmithKline today announced that, following a recommendation by the Independent Data Monitoring Committee, it has taken the decision to stop enrolling patients in the Phase II INDUCE-3 trial, including discontinuing treatment with feladilimab. 15 April 2021
China’s SciNeuro Pharmaceuticals has entered into an exclusive license agreement with US pharma major Eli Lilly for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. 15 April 2021
Pfizer and BioNTech’s Comirnaty (tozinameran) is forecast to have peak sales of $24.8 billion by 2021, which is only its second year on the market. 15 April 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.